|
1
|
Yun J, Saddawi-Konefka R, Goldenson B, Al-Msari R, Bernareggi D, Thangaraj JL, Tang S, Patel SH, Luna SM, Gutkind JS, Kaufman D. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model. J Immunother Cancer 2024; 12:e007187. [PMID: 38702144 PMCID: PMC11086353 DOI: 10.1136/jitc-2023-007187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2024] [Indexed: 05/06/2024] Open
Abstract
BACKGROUND Natural killer (NK) cells are key effector cells of antitumor immunity. However, tumors can acquire resistance programs to escape NK cell-mediated immunosurveillance. Identifying mechanisms that mediate this resistance enables us to define approaches to improve immune-mediate antitumor activity. In previous studies from our group, a genome-wide CRISPR-Cas9 screen identified Charged Multivesicular Body Protein 2A (CHMP2A) as a novel mechanism that mediates tumor intrinsic resistance to NK cell activity. METHODS Here, we use an immunocompetent mouse model to demonstrate that CHMP2A serves as a targetable regulator of not only NK cell-mediated immunity but also other immune cell populations. Using the recently characterized murine 4MOSC model system, a syngeneic, tobacco-signature murine head and neck squamous cell carcinoma model, we deleted mCHMP2A using CRISPR/Cas9-mediated knock-out (KO), following orthotopic transplantation into immunocompetent hosts. RESULTS We found that mCHMP2A KO in 4MOSC1 cells leads to more potent NK-mediated tumor cell killing in vitro in these tumor cells. Moreover, following orthotopic transplantation, KO of mCHMP2A in 4MOSC1 cells, but not the more immune-resistant 4MOSC2 cells enables both T cells and NK cells to better mediate antitumor activity compared with wild type (WT) tumors. However, there was no difference in tumor development between WT and mCHMP2A KO 4MOSC1 or 4MOSC2 tumors when implanted in immunodeficient mice. Mechanistically, we find that mCHMP2A KO 4MOSC1 tumors transplanted into the immunocompetent mice had significantly increased CD4+T cells, CD8+T cells. NK cell, as well as fewer myeloid-derived suppressor cells (MDSC). CONCLUSIONS Together, these studies demonstrate that CHMP2A is a targetable inhibitor of cellular antitumor immunity.
Collapse
Affiliation(s)
- Jiyoung Yun
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
- Dept. of Medicine, University of California-San Diego, La Jolla, California, USA
- Sanford Stem Cell Institute, University of California-San Diego, La Jolla, California, USA
| | - Robert Saddawi-Konefka
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
- Dept. of Otolaryngology-Head and Neck Surgery, University of California-San Diego, La Jolla, California, USA
| | - Benjamin Goldenson
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
- Dept. of Medicine, University of California-San Diego, La Jolla, California, USA
- Sanford Stem Cell Institute, University of California-San Diego, La Jolla, California, USA
| | - Riyam Al-Msari
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
| | - Davide Bernareggi
- Dept. of Medicine, University of California-San Diego, La Jolla, California, USA
| | - Jaya L Thangaraj
- Dept. of Medicine, University of California-San Diego, La Jolla, California, USA
- Sanford Stem Cell Institute, University of California-San Diego, La Jolla, California, USA
| | - Shiqi Tang
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
| | - Sonam H Patel
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
| | - Sarah M Luna
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
| | - J Silvio Gutkind
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
- Dept. of Pharmacology, University of California School of Medicine, La Jolla, California, USA
| | - Dan Kaufman
- Moores Cancer Center, University of California-San Diego, La Jolla, California, USA
- Dept. of Medicine, University of California-San Diego, La Jolla, California, USA
- Sanford Stem Cell Institute, University of California-San Diego, La Jolla, California, USA
| |
Collapse
|
|
2
|
Wu Z, You C, Zhu Z, Wu W, Cao J, Xie Q, Deng C, Huang X, Hu S. SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment. Eur Arch Otorhinolaryngol 2024; 281:427-440. [PMID: 37688682 PMCID: PMC10764518 DOI: 10.1007/s00405-023-08213-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Accepted: 08/25/2023] [Indexed: 09/11/2023]
Abstract
PURPOSE To investigate Src-like adaptor 2 gene (SLA2) expression in head and neck squamous cell carcinoma (HNSCC), its potential prognostic value, and its effect on immune cell infiltration. METHODS Through a variety of bioinformatics analyses, we extracted and analyzed data sets from the Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER), and Gene Expression Profile Interaction Analysis (GEPIA) to analyze the correlation between SLA2 and the prognosis, immune checkpoint, tumor microenvironment (TME) and immune cell infiltration of HNSCC, and to explore its potential oncogenic mechanism. To further explore the potential role of SLA2 in HNSCC by Gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. RESULTS SLA2 messenger ribonucleic acid (mRNA) levels were increased in HNSCC tumor tissues compared with normal tissues. In addition, we found that SLA2 may be an independent prognostic factor for HNSCC, and high SLA2 expression is associated with favorable prognosis in HNSCC. SLA2 expression was positively correlated with B cells, cluster of differentiation 8-positive T cells (CD8 + T cells), cluster of differentiation 4-positive T cells (CD4 + T cells), macrophages, neutrophil and dendritic cells infiltration. SLA2 has also been shown to co-express immune-related genes and immune checkpoints. Significant GO term analysis by Gene Set Enrichment Analysis (GSEA) indicated that genes correlated with SLA2 were located mainly in the side of membrane, receptor complex, secretory granule membrane, endocytic vesicle, membrane region, and endosome membrane, where they were involved in leukocyte cell-cell adhesion, response to interferon-gamma, and regulation of immune effector process. These related genes also served as antigen binding, cytokine receptor activity, phosphatidylinositol 3-kinase activity, peptide receptor activity, Src homology domain 3 (SH3) domain binding, and cytokine receptor binding. KEGG pathway analysis demonstrated that these genes related to SLA2 were mainly enriched in signal pathways, such as hematopoietic cell lineage, cell adhesion molecules (CAMs), natural killer cell mediated cytotoxicity, measles, and chemokine signaling pathway. CONCLUSIONS SLA2 is increased in HNSCC, and high SLA2 expression is associated with favorable prognosis. SLA2 may affect tumor development by regulating tumor infiltrating cells in TME. SLA2 may be a potential target for immunotherapy.
Collapse
Affiliation(s)
- Zhongbiao Wu
- Department of Otolaryngology, Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine, 90 Bayi Avenue, Xihu District, Nanchang, 330003, Jiangxi, China
| | - Chengkun You
- Department of Neurology, Pinghu Hospital of Traditional Chinese Medicine, Jiaxing, 314200, China
| | - Zhongyan Zhu
- Department of Rehabilitation, Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine, Nanchang, 330003, China
| | - Weikun Wu
- Department of Otolaryngology, Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine, 90 Bayi Avenue, Xihu District, Nanchang, 330003, Jiangxi, China
| | - Jian Cao
- Department of Otolaryngology, Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine, 90 Bayi Avenue, Xihu District, Nanchang, 330003, Jiangxi, China
| | - Qiang Xie
- Department of Otolaryngology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330019, China
| | - Chengcheng Deng
- Department of Otolaryngology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330019, China
| | - Xinmei Huang
- Department of Otolaryngology, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, Jiangxi, China
| | - Shiping Hu
- Department of Otolaryngology, Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine, 90 Bayi Avenue, Xihu District, Nanchang, 330003, Jiangxi, China.
| |
Collapse
|
|
3
|
Parikh AS, Li Y, Mazul A, Yu VX, Thorstad W, Rich J, Paniello RC, Caruana SM, Troob SH, Jackson RS, Pipkorn P, Zolkind P, Qi Z, Adkins D, Ding L, Puram SV. Immune Cell Deconvolution Reveals Possible Association of γδ T Cells with Poor Survival in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2023; 15:4855. [PMID: 37835549 PMCID: PMC10571517 DOI: 10.3390/cancers15194855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/02/2023] [Accepted: 10/03/2023] [Indexed: 10/15/2023] Open
Abstract
(1) Background: The role of rare immune cell subtypes in many solid tumors, chief among them head and neck squamous cell carcinoma (HNSCC), has not been well defined. The objective of this study was to assess the association between proportions of common and rare immune cell subtypes and survival outcomes in HNSCC. (2) Methods: In this cohort study, we utilized a deconvolution approach based on the CIBERSORT algorithm and the LM22 signature matrix to infer proportions of immune cell subtypes from 517 patients with untreated HPV-negative HNSCC from The Cancer Genome Atlas. We performed univariate and multivariable survival analysis, integrating immune cell proportions with clinical, pathologic, and genomic data. (3) Results: We reliably deconvolved 22 immune cell subtypes in most patients and found that the most common immune cell types were M0 macrophages, M2 macrophages, and memory resting CD4 T cells. In the multivariable analysis, we identified advanced N stage and the presence of γδ T cells as independently predictive of poorer survival. (4) Conclusions: We uncovered that γδ T cells in the tumor microenvironment were a negative predictor of survival among patients with untreated HNSCC. Our findings underscore the need to better understand the role of γδ T cells in HNSCC, including potential pro-tumorigenic mechanisms, and whether their presence may predict the need for alternative therapy approaches.
Collapse
Affiliation(s)
- Anuraag S. Parikh
- Department of Otolaryngology—Head and Neck Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA; (V.X.Y.); (S.M.C.); (S.H.T.)
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Yize Li
- Department of Medicine, Division of Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA (D.A.); (L.D.)
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, USA
| | - Angela Mazul
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Victoria X. Yu
- Department of Otolaryngology—Head and Neck Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA; (V.X.Y.); (S.M.C.); (S.H.T.)
| | - Wade Thorstad
- Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA;
| | - Jason Rich
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Randal C. Paniello
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Salvatore M. Caruana
- Department of Otolaryngology—Head and Neck Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA; (V.X.Y.); (S.M.C.); (S.H.T.)
| | - Scott H. Troob
- Department of Otolaryngology—Head and Neck Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA; (V.X.Y.); (S.M.C.); (S.H.T.)
| | - Ryan S. Jackson
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Patrik Pipkorn
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Paul Zolkind
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Zongtai Qi
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
| | - Douglas Adkins
- Department of Medicine, Division of Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA (D.A.); (L.D.)
| | - Li Ding
- Department of Medicine, Division of Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA (D.A.); (L.D.)
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, USA
- Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63108, USA
- Department of Genetics, Washington University School of Medicine, St. Louis, MO 63108, USA
| | - Sidharth V. Puram
- Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA; (A.M.); (J.R.); (R.C.P.); (R.S.J.); (P.P.); (P.Z.); (Z.Q.)
- Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63108, USA
- Department of Genetics, Washington University School of Medicine, St. Louis, MO 63108, USA
| |
Collapse
|
|
4
|
Nowak J, Bentele M, Kutle I, Zimmermann K, Lühmann JL, Steinemann D, Kloess S, Koehl U, Roßberg W, Ahmed A, Schaudien D, Neubert L, Kamp JC, Kuehnel MP, Warnecke A, Schambach A, Morgan M. CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers (Basel) 2023; 15:3169. [PMID: 37370779 DOI: 10.3390/cancers15123169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 06/06/2023] [Accepted: 06/08/2023] [Indexed: 06/29/2023] Open
Abstract
(1) Background: HNSCC is a highly heterogeneous and relapse-prone form of cancer. We aimed to expand the immunological tool kit against HNSCC by conducting a functional screen to generate chimeric antigen receptor (CAR)-NK-92 cells that target HER1/epidermal growth factor receptor (EGFR). (2) Methods: Selected CAR-NK-92 cell candidates were tested for enhanced reduction of target cells, CD107a expression and IFNγ secretion in different co-culture models. For representative HNSCC models, patient-derived primary HNSCC (pHNSCC) cell lines were generated by employing an EpCAM-sorting approach to eliminate the high percentage of non-malignant cells found. (3) Results: 2D and 3D spheroid co-culture experiments showed that anti-HER1 CAR-NK-92 cells effectively eliminated SCC cell lines and primary HNSCC (pHNSCC) cells. Co-culture of tumor models with anti-HER1 CAR-NK-92 cells led to enhanced degranulation and IFNγ secretion of NK-92 cells and apoptosis of target cells. Furthermore, remaining pHNSCC cells showed upregulated expression of putative cancer stem cell marker CD44v6. (4) Conclusions: These results highlight the promising potential of CAR-NK cell therapy in HNSCC and the likely necessity to target multiple tumor-associated antigens to reduce currently high relapse rates.
Collapse
Affiliation(s)
- Juliette Nowak
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Marco Bentele
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Ivana Kutle
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | - Katharina Zimmermann
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| | | | - Doris Steinemann
- Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
| | - Stephan Kloess
- Institute for Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany
| | - Ulrike Koehl
- Institute for Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany
- Institute of Clinical Immunology, University Leipzig, 04103 Leipzig, Germany
- Fraunhofer Institute for Cell Therapy and Immunology, IZI, 04103 Leipzig, Germany
| | - Willi Roßberg
- Department of Otolaryngology, Head and Neck Surgery, Hannover Medical School, 30625 Hannover, Germany
| | - Amed Ahmed
- Department of Otolaryngology, Head and Neck Surgery, Hannover Medical School, 30625 Hannover, Germany
| | - Dirk Schaudien
- Fraunhofer Institute for Toxicology and Experimental Medicine, ITEM, 30625 Hannover, Germany
| | - Lavinia Neubert
- Institute of Pathology, Hannover Medical School, 30625 Hannover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany
| | - Jan-Christopher Kamp
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany
- Department of Respiratory Medicine, Hannover Medical School, 30625 Hannover, Germany
| | - Mark P Kuehnel
- Institute of Pathology, Hannover Medical School, 30625 Hannover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany
| | - Athanasia Warnecke
- Department of Otolaryngology, Head and Neck Surgery, Hannover Medical School, 30625 Hannover, Germany
| | - Axel Schambach
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
- Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Michael Morgan
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
| |
Collapse
|
|
5
|
Chang SR, Chou CH, Liu CJ, Lin YC, Tu HF, Chang KW, Lin SC. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas. Int J Mol Sci 2023; 24:ijms24065931. [PMID: 36983005 PMCID: PMC10054118 DOI: 10.3390/ijms24065931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 03/13/2023] [Accepted: 03/20/2023] [Indexed: 03/30/2023] Open
Abstract
Immune modulation is a critical factor in determining the survival of patients with malignancies, including those with oral squamous cell carcinoma (OSCC) and head and neck SCC (HNSCC). Immune escape or stimulation may be driven by the B7/CD28 family and other checkpoint molecules, forming ligand-receptor complexes with immune cells in the tumor microenvironment. Since the members of B7/CD28 can functionally compensate for or counteract each other, the concomitant disruption of multiple members of B7/CD28 in OSCC or HNSCC pathogenesis remains elusive. Transcriptome analysis was performed on 54 OSCC tumors and 28 paired normal oral tissue samples. Upregulation of CD80, CD86, PD-L1, PD-L2, CD276, VTCN1, and CTLA4 and downregulation of L-ICOS in OSCC relative to the control were noted. Concordance in the expression of CD80, CD86, PD-L1, PD-L2, and L-ICOS with CD28 members was observed across tumors. Lower ICOS expression indicated a worse prognosis in late-stage tumors. Moreover, tumors harboring higher PD-L1/ICOS, PD-L2/ICOS, or CD276/ICOS expression ratios had a worse prognosis. The survival of node-positive patients was further worsened in tumors exhibiting higher ratios between PD-L1, PD-L2, or CD276 and ICOS. Alterations in T cell, macrophage, myeloid dendritic cell, and mast cell populations in tumors relative to controls were found. Decreased memory B cells, CD8+ T cells, and Tregs, together with increased resting NK cells and M0 macrophages, occurred in tumors with a worse prognosis. This study confirmed frequent upregulation and eminent co-disruption of B7/CD28 members in OSCC tumors. The ratio between PD-L2 and ICOS is a promising survival predictor in node-positive HNSCC patients.
Collapse
Affiliation(s)
- Shi-Rou Chang
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Chung-Hsien Chou
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Chung-Ji Liu
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Stomatology, Taipei Mackay Memorial Hospital, Taipei 104217, Taiwan
| | - Yu-Cheng Lin
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Hsi-Feng Tu
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Kuo-Wei Chang
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Stomatology, Taipei Veterans General Hospital, Taipei 112201, Taiwan
| | - Shu-Chun Lin
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Stomatology, Taipei Veterans General Hospital, Taipei 112201, Taiwan
| |
Collapse
|
|
6
|
Ge Y, Xia J, He C, Liu S. Identification of circRNA-lncRNA-miRNA-mRNA competitive endogenous RNA networks as prognostic bio-markers in head and neck squamous cell carcinoma. Technol Health Care 2023; 31:2193-2212. [PMID: 37522233 DOI: 10.3233/thc-230083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/01/2023]
Abstract
BACKGROUND Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent neoplasms of malignancy. The pathogenesis of HNSCC is involved in the change of gene expression and the abnormal interaction between genes. OBJECTIVE The purpose of our research is to find genes that affect the survival time of patients and construct circRNA-lncRNA-miRNA-mRNA network. This paper aims to reveal the development mechanism of HNSCC and provide new ideas for clinical prognosis prediction. METHODS Transcriptome data were obtained from TCGA and GEO databases. A total of 556 samples were included. We screened the differentially expressed lncRNAs, circRNAs and mRNAs to predict interactions between lncRNA-miRNA, circRNA-miRNA and miRNA-mRNA. Then, we selected the hub mRNAs to predict the prognosis of patients. RESULTS We identified 8 hub prognostic mRNAs (FAM111A, IFIT2, CAV1, KLF9, OCIAD2, SLCO3A1, S100A16 and APOL3) by a series of bioinformatics analyses and established the prognostic ceRNA network of 8 mRNAs, 3 miRNAs, 2 circRNAs and 1 lncRNAs according to the targeting relationship by using databases. CONCLUSION We established the circRNA-lncRNA-miRNA-mRNA gene interaction network in HNSCC. We illuminated the molecular mechanism underlying the gene regulation associated with the pathogenesis of HNSCC and predicted the biomarkers related to prognosis.
Collapse
|
|
7
|
Zhao F, Liu Y, Tan F, Tang L, Du Z, Mou J, Zhou G, Yuan C. MIR4435-2HG：A tumor-associated long non-coding RNA. Curr Pharm Des 2022; 28:2043-2051. [PMID: 35674305 DOI: 10.2174/1381612828666220607100228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Accepted: 03/10/2022] [Indexed: 11/22/2022]
Abstract
BACKGROUND It is well known that the changes in the expression level of LncRNA can affect the progression of tumors, which has caused a great upsurge of research in recent years. More and more LncRNA has been proved to take effect on a series of cancers and can promote tumor growth, migration and invasion. In this review, we aim to clarify the pathophysiological functions of LncRNA -MIR4435-2 HG in multiple tumors can be elucidated. METHODS By consulting the literature through PubMed, this paper summarizes the relationship between MIR4435-2HG and tumor and its role in the occurrence and development of cancer, and also expounds the specific molecular mechanism of the effect of MIR4435-2HG on cancer. RESULTS MIR4435-2HG can function as an oncogene in a variety of cancers. The expression level was abnormally elevated in a series of cancers, consisting of melanoma gastric cancer, head and neck squamous cell carcinoma, oral squamous cell carcinoma, lung cancer, cervical cancer, prostate carcinoma, ovarian cancer, breast cancer, hepatocellular Carcinoma, clear cell renal cell carcinoma malignant, glioma and colorectal cancer. Moreover, MIR4435-2HG is related to the poor prognosis of a variety of cancers. MIR4435-2HG can also affect tumor proliferation, invasion and apoptosis. In addition, MIR4435-2HG can also enhance the metabolic function of myeloid dendritic cells of elite HIV-1 controllers. CONCLUSION MIR4435-2HG affects the development of a variety of cancers. It can act as a clinical marker for early tumor diagnosis and takes effects to tumor targeted therapy.
Collapse
Affiliation(s)
- Fangnan Zhao
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| | - Yuling Liu
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| | - Fangshun Tan
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| | - Lu Tang
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| | - Zhuoying Du
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| | - Jie Mou
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| | - Gang Zhou
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.,Yichang Hospital of Traditional Chinese Medicine, Yichang, 443002, China
| | - Chengfu Yuan
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine，State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China.,Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China
| |
Collapse
|